Lisle, Ill.-based medtech company Endotronix Inc. secured $45 million in a Series D financing round.

Athersys Inc. and Mesoblast Ltd. are beginning final-stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.

Johnson & Johnson’s Janssen Biotech opted out of its licensing deal with Los Angeles-based Capricor Therapeutics for CAP-1002 (allogeneic cardiosphere-derived cells).